Abbisko Cayman Ltd
HKEX:2256

Watchlist Manager
Abbisko Cayman Ltd Logo
Abbisko Cayman Ltd
HKEX:2256
Watchlist
Price: 9.95 HKD -8.21% Market Closed
Market Cap: 6.7B HKD
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one Abbisko Cayman Ltd stock under the Base Case scenario is hidden HKD. Compared to the current market price of 9.95 HKD, Abbisko Cayman Ltd is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

Abbisko Cayman Ltd Relative Value
HIDDEN
Show
Worst Case
Base Case
Best Case

Valuation Multiples

12.7
P/S
P/S
Price to Sales
12.7
vs History
52
vs Industry
43
Median 3Y
79.1
Median 5Y
80.1
Industry
7.2
Forward
13.3
More Details
225.7
P/E
P/E
Price to Earnings
225.7
vs History
0
vs Industry
Median 3Y
-3.6
Median 5Y
-3.6
Industry
23.2
Forward
-82.7
More Details
Negative
P/OCF
P/OCF
Price to OCF
N/A
vs History
vs Industry
Median 3Y
-7.4
Median 5Y
-9.3
Industry
19.3
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
Median 3Y
-5.7
Median 5Y
-5.5
Industry
22.5
More Details
3
P/B
P/B
Price to Book Value
3
vs History
0
vs Industry
37
Median 3Y
0.9
Median 5Y
0.9
Industry
2.7
More Details
8.5
EV/S
EV/S
Enterprise Value to Sales
8.5
vs History
13
vs Industry
46
Median 3Y
-4.1
Median 5Y
-4.1
Industry
7.5
Forward
8.9
More Details
8.5
EV/GP
EV/GP
Enterprise Value to Gross Profit
8.5
vs History
13
vs Industry
52
Median 3Y
-4.1
Median 5Y
-4.1
Industry
9.4
More Details
41.5
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
41.5
vs History
4
vs Industry
13
Median 3Y
0.6
Median 5Y
0.3
Industry
4.6
Forward
90.5
More Details
53.8
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
53.8
vs History
0
vs Industry
11
Median 3Y
0.6
Median 5Y
0.3
Industry
4.5
Forward
141.3
More Details
Negative
EV/OCF
EV/OCF
Enterprise Value to OCF
N/A
vs History
vs Industry
15
Median 3Y
0.5
Median 5Y
0.1
Industry
4.9
More Details
Negative
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
N/A
vs History
vs Industry
11
Median 3Y
0.5
Median 5Y
0.1
Industry
3.7
More Details
31.7
EV/IC
EV/IC
Enterprise Value to IC
31.7
vs History
4
vs Industry
11
Median 3Y
-0.9
Median 5Y
-0.3
Industry
4.9
More Details

Multiples Across Competitors

Competitors Multiples
Abbisko Cayman Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
CN
Abbisko Cayman Ltd
HKEX:2256
7B HKD 12.7 225.7 41.5 53.8
FR
Pharnext SCA
OTC:PNEXF
6T USD 34 345 565.3 -163 239.4 -198 224.7 -195 962.7
US
Abbvie Inc
NYSE:ABBV
332.5B USD 5.8 80.1 15.2 22.5
US
Amgen Inc
NASDAQ:AMGN
158.5B USD 4.6 26.7 14.4 23.7
US
Gilead Sciences Inc
NASDAQ:GILD
135.6B USD 4.7 22.7 9.9 13.7
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
114.8B USD 10.4 -116.5 24.7 25.8
US
Epizyme Inc
F:EPE
94.1B EUR 2 051.2 -523.4 -569.9 -554.7
AU
CSL Ltd
ASX:CSL
115.9B AUD 5 27.5 17 21.3
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
56.5B USD 4 12.5 11.1 12.5
US
Seagen Inc
F:SGT
39.3B EUR 19.8 -60.6 -65.3 -58.9
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
39.6B USD 16.9 -147.2 -657.9 -329.7
P/E Multiple
Earnings Growth PEG
CN
Abbisko Cayman Ltd
HKEX:2256
Average P/E: 65.9
225.7
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -163 239.4 N/A N/A
US
Abbvie Inc
NYSE:ABBV
80.1
88%
0.9
US
Amgen Inc
NASDAQ:AMGN
26.7
45%
0.6
US
Gilead Sciences Inc
NASDAQ:GILD
22.7
188%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -116.5 N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -523.4 N/A N/A
AU
CSL Ltd
ASX:CSL
27.5
16%
1.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
12.5
7%
1.8
US
S
Seagen Inc
F:SGT
Negative Multiple: -60.6 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -147.2 N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
CN
Abbisko Cayman Ltd
HKEX:2256
Average EV/EBITDA: 19.1
41.5
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -198 224.7 N/A N/A
US
Abbvie Inc
NYSE:ABBV
15.2
13%
1.2
US
Amgen Inc
NASDAQ:AMGN
14.4
17%
0.8
US
Gilead Sciences Inc
NASDAQ:GILD
9.9
6%
1.7
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24.7
17%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -569.9 N/A N/A
AU
CSL Ltd
ASX:CSL
17
11%
1.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
11.1
11%
1
US
S
Seagen Inc
F:SGT
Negative Multiple: -65.3 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -657.9 N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
CN
Abbisko Cayman Ltd
HKEX:2256
Average EV/EBIT: 24.7
53.8
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -195 962.7 N/A N/A
US
Abbvie Inc
NYSE:ABBV
22.5
29%
0.8
US
Amgen Inc
NASDAQ:AMGN
23.7
32%
0.7
US
Gilead Sciences Inc
NASDAQ:GILD
13.7
11%
1.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
25.8
17%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -554.7 N/A N/A
AU
CSL Ltd
ASX:CSL
21.3
14%
1.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
12.5
11%
1.1
US
S
Seagen Inc
F:SGT
Negative Multiple: -58.9 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -329.7 N/A N/A

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 262,200+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.